artivabio

Artiva was featured in San Diego Business Journal following its $300 million financing to support the continued advancement of AlloNK in autoimmune disease. The article discusses the company's planned Phase 3 trial in refractory rheumatoid arthritis and i

Over the past decade, CAR-T therapies have demonstrated curative potential, while also underscoring how complexity, cost, and infrastructure can limit the number of patients who can be treated. In this episode of the Biotech2050 podcast, Artiva's CEO Fred

In rheumatoid arthritis, existing therapies frequently fall short of delivering sustained disease control, despite sequential use of biologic and targeted agents. In a this episode of the 𝗕𝗮𝘀𝗲 𝘁𝗼 𝗕𝗮𝘀𝗲 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗣𝗼𝗱𝗰𝗮𝘀𝘁, Lisa Guerrettaz, Executive Director,

SDBJ: Artiva Bio Soaring on Focus Shift from Oncology to Autoimmune Disease Artiva Biotherapeutics was featured in the San Diego Business Journal highlighting the Company's strategic transition into autoimmune disease and the FDA Fast Track Designation fo

Inside Precision Medicine spoke with Artiva's Chief Medical Officer, Dr. Subhashis Banerjee, about our clinical development approach for AlloNK in autoimmune disease. In the Q&A, Dr. Banerjee outlines how we are advancing AlloNK through a parallel trial s